Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BGB 16673

Next Previous
X
Search
Drug Profile

BGB 16673

Alternative Names: BGB-1663; BGB-16673; Chimeric Degradation Activating Compound (CDAC) targeting BTK - BeiGene

Latest Information Update: 15 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BeiGene
  • Class Antineoplastics
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Phase I Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 08 May 2024 BeiGene plans a phase III trial for Chronic lymphocytic leukemia by the end of 2024
  • 26 Feb 2024 BGB 16673 receives Orphan Drug status for Mantle-cell lymphoma (Second-line therapy or greater) in USA
  • 26 Feb 2024 BGB 16673 receives Fast Track designation for Mantle cell lymphoma (Second-line therapy or greater) in USA before February 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top